Kornimate/medical-research-clean huggingface dataset:
the association between visual echocardiographic scoring system and clinical outcomes in patient with acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: this study aims to evaluate the association between visual echocardiographic scoring system (visual mitral and tricuspid = vmt score) with clinical outcome among patients with acute decompensated heart failure. researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as acute decompensated heart failure. the data consist of demographic data, clinical presentation, laboratory, and echocardiographic result were collected from hospital registry by reviewing medical record and echocardiographic machine database. then, the data was analyzed by using ibm spss statistics v26.


Eligibility criteria:
inclusion criteria: * patient with history of heart failure with reduced ejection fraction (lvef \<40%) * age between 18 - 70 years old exclusion criteria: * patient with pulmonary hypertension * patient with acute de novo heart failure (e.g. due to acute coronary syndrome) * significant valvular heart disease (more than moderate regurgitation or more than mild stenosis) * prior valve replacement/repair * patient with congenital heart disease * patient with pericardial disease * patient with poor echocardiographic images

Keywords: visual echocardiographic system acute decompensated heart failure mortality
artificial intelligence-assisted colonoscopy with or without endocuff vision

Conditions: Adenoma Detection Rate

Summary: adenoma detection rate (adr) is considered the single most important quality measure in colonoscopy and a higher adr can reduce the risk of interval colorectal cancer (crc). several kinds of new endoscopes and accessories have been accessed to investigate the abilities of improving the adr. artificial intelligence (ai) and endocuff vision are promising new devices to improve the adr. however, the effect of combining ai and endocuff vision on adr remains unclear. the aim of this prospective randomized study is to compare the adr of ai plus endocuff vision, ai alone and standard colonoscopy examination.

this is a prospective single-blinded randomized controlled trial of three different types of colonoscopy examinations by 1:1:1 ratio. we use endoaim ai (asus, taiwan) and endocuff vision (olympus, uk) assisted colonoscopy in the first group. we use ai assisted colonoscopy in the 2nd group. we use standard colonoscopy in the 3rd group. eligible patients are older than 40 years old and receive colonoscopy for either symptomatic or screening/surveillance. all endoscopists should receive training on endoaim ai systems and endocuff vision. during the procedure, experienced endoscopists use high-definition endoscopes (evis-exera 290 video system, olympus optical, aizu, japan) under white light and insert to the cecum in the three different groups. the cecal intubation is confirmed by the identification of ileocecal valve and appendiceal orifice. the boston bowel preparation scale is used for grading the bowel preparation quality. the size (compared with biopsy forceps), location and morphology of polyps are recorded by the independent endoscopist. all polyps ae removed by either biopsy or polypectomy. the insertion and withdrawal time are measured. the time of the polypectomy site is not included in the withdrawal time.

Eligibility criteria:
inclusion criteria: patients over 20 years old are undergoing outpatient sedative colonoscopy in the e-da hospital, e-da cancer hospital and chung shan medical university hospital in taiwan exclusion criteria: * a prior history of of inflammatory bowel disease, colorectal cancer, previous bowel resection, peutz-jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes * bleeding tendency * for scheduled endoscopic treatment
impact of blood flow restriction and electrical stimulation on postoperative muscle atrophy and pain after total knee arthroplasty

Conditions: Osteoarthritis Knees

Summary: this study investigate the impact of blood flow restriction training and electrostimulation training on postoperative muscle atrophy and pain after elective total knee arthroplasty.

the present study invesigate the impact of passive blood flow restriction training and/or electrical stimulation training on postoperative muscle atrophy and pain after elective total knee arthroplasty.

Eligibility criteria:
inclusion criteria: * indication for elective total knee arthroplasty * understanding of the study and ability for informed consent exclusion criteria: * open wounds of the lower extremities * stents or bypasses on the location of pressure application * sickle cell anemia
the oct sort-out viii study

Conditions: Coronary Artery Disease; Angina Pectoris; Myocardial Infarction

Summary: the purpose of this study is to compare early vessel healing after implantation of synergy drug eluting stent (des) or biomatrix neoflex des at one and three months in two cohorts.

prospective, open label, single blind, randomized study with inclusion of 160 patients in two equal sized cohorts (a and b). angiographic follow-up with optical coherence tomography (oct) is performed at 1 month (cohort a) and 3 months (cohort b). randomization 1:1 to synergy or biomatrix neoflex. the cohorts are included consecutively, cohort a first.

Eligibility criteria:
inclusion criteria: * patients \>18 years to be treated with one or more drug-eluting stents in a coronary artery at aarhus university hospital or odense university hospital exclusion criteria: * age \<18 years * do not wish to participate * unable to provide written informed consent * domicile outside denmark * do not speak danish * inclusion in the sort-out viii study * inclusion in other stent studies * expected survival \<1 year * allergy to aspirin, clopidogrel, prasugrel or ticagrelor * hypersensitivity to everolimus or biolimus * the operator wishes to use other des * reduced renal function; creatinine\> 120 mmol / l * only bare metal stent (bms) implantation * only plain old balloon angioplasty (poba)

Keywords: des angina pectoris stent optical coherence tomography stent thrombosis
amitriptyline regarding nimesulide in acute idiopathic adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the adhesive capsulitis is a disease of the shoulder characterized by pain and limitation of movement amplitude. it is defined as for etiology, having discordant theories that related it to an inflammatory condition or to an algoneurodystrophy process. there is not yet a consensus about the best option of treatment. the non-steroidal anti-inflammatories have analgesic and anti-inflammatory activity, where the mechanism of action is the inhibition of prostaglandin synthesis. the antidepressants have been increasingly used in the control of chronic pain and the major action mechanism to have the analgesic effect seems to be based on inhibition of neurotransmitters reuptake noradrenaline and/or serotonin) in nerve cell endings. literature studies associate the practice of the nerve suprascapular blockade with anaesthetics to good results of clinical improvement of the pain, however, so far, no clinical studies comparing the efficacy of the non-steroidal antiinflammatories or tricyclic antidepressants to nervous blockage were registered in the acute treatment of adhesive capsulitis.


Eligibility criteria:
inclusion criteria: * patients with clinical diagnostic of adhesive capsulitis, phase ii, presenting shoulder pain, * limitation of anterior elevation for up to 130 degrees, * intact rotator cuff to magnetic resonance, * minimum loss of 50% of external rotation when compared to the contralateral side. * patients' acceptance of take part in the study after signing the fcct. exclusion criteria: * incapacity to fill the evaluation instrument; * contraindication to the use of local anaesthetics, non-steroidal anti-inflammatories or tricyclic antidepressants. * pregnancy and breastfeeding. * not follow the orientations during treatment on the weeks included in the study, such as, using other anaesthetics or procedures for the relief of pain in this period. * lesion of the rotator cuff, infection and others arthropathies. * inability to fill a protocol. * previous surgery on the shoulder.

Keywords: adhesive capsulitis shoulder spadi
a safety study of 212pb-pentixather radioligand therapy

Conditions: Carcinoid Tumor Lung; Neuroendocrine Tumor of the Lung; Carcinoma, Small-Cell Lung

Summary: this is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (lead-212 labelled pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.

this is a study to determine what dose is acceptably safe for further testing. in this study, participants are asked to: * undergo spect/ct imaging with lead-203 pentixather (a radiotracer) to ensure the tumor lesions have the needed receptors * undergo serial blood sampling for during and after the spect/ct scan for radiation and dosimetry calculations (to determine how much of the lead-212 pentixather to administer) * receive up to 2 infusions of arginine \& lysine as a kidney protectant * receive up to 2 infusions of lead-212 pentixather, 6 weeks between each infusion * undergo imaging at 3 months post treatment to determine disease response

Eligibility criteria:
inclusion criteria: * ability to provide independent consent * adequate bone marrow function (platelet count ≥ 100,000; hemoglobin of ≥ 10 g/dl; neutrophil count ≥ 1,500 cells/mm3) * adequate kidney function (creatinine clearance of ≥ 50 ml/min using the cockcroft-gault equation * adequate liver function (serum bilirubin ≤ 3x the upper limit of normal, ast ≤ 5x the upper limit of normal, and alt ≤ 5x the upper limit of normal) * failed initial therapy or declined further therapy known to confer benefit * have at least one lesion ≥ 2 cm that is positive for cxcr4 as demonstrated by lead-203 pentixather spect/ct exclusion criteria: * major surgery within 4 weeks of consent * antoher investigational agent within 4 weeks of consent * uncontrolled illness including, but not limited to, ongoing or active infection that would necessitate a delay in therapy or cause a hospital admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness/social situations that would limit compliance with study requirements. * prior solid organ transplant * cytotoxic or antineoplastic therapy within 21 days of consent (42 days for nitrosoureas) * antibody therapy within the 21 days of consent * allogenic bone marrow or stem cell transplant, or any stem cell infusion, within 84 days of consent * pregnancy * breastfeeding * refusal to comply with birth control requirements during study

Keywords: radioligand therapy pentixather lead 203 lead 212 alpha therapy dosimetry
3e extension study

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to evaluate the long-term efficacy and safety of entecavir 0.5 mg/d + adefovir 10 mg/d for treatment experienced chronic hepatitis b patients.


Eligibility criteria:
inclusion criteria: * subjects who completed the explore or excel studies, or subjects with hepatitis flare after treatment withdrawal in effort study. * subjects who are willing to participate the extension study. exclusion criteria: * subjects who could not compliance with the protocol judged by investigators

Keywords: experienced treatment
stronger together psoriatic arthritis wellness study

Conditions: Psoriatic Arthritis

Summary: patients diagnosed with psoriatic arthritis (psa) confront decisions about how to treat their disease, interact with their health care providers, and modify lifestyle choices that may improve treatment outcomes. with sponsorship support from janssen and in partnership with the cleveland clinic, this survey study will seek to understand and examine whether people living with psa are interested in and motivated to participate in wellness activities. this cross-sectional observational survey study will help researchers and clinicians to better understand what some of the barriers and facilitators experienced by patients are when considering participation in guided online wellness activities. people that qualify for the study and complete a 10-minute survey will be invited to participate in immune strength, an online wellness program developed by the cleveland clinic. immune strength is a free 10-week program for creating better habits for a more resilient immune system. by following this program, participants will have the opportunity to learn about how to develop strategies and implement behavior changes for healthier immune functioning. participants will be recruited by the global healthy living foundation (ghlf). ghlf is the parent organization of the creakyjoints® (cj) arthritis patient community and primary site for the pcori-funded arthritis patient partnership with comparative effectiveness researchers (ar-power) patient powered research network (pprn), known as arthritispower®. arthritispower is a subset of creakyjoints members who have expressed interest in participating in research and signed an informed consent form to participate in the pprn and its associated research. any individuals recruited from creakyjoints or facebook, who are not already members of arthritispower will be encouraged to join the arthritispower registry research app, but will not be required to do so in order to participate in the study.


Eligibility criteria:
inclusion criteria: * participants must be residents of the united states and united states territories * participants must be age 19 and above for united states resident or 21 and above for puerto rico residents * participants must have a self-reported diagnosis of psoriatic arthritis (psa) (as indicated by survey screening questions) * participants must be taking prescribed medication to treat their psa * participants must have access to a computer or smartphone to take the survey
effectiveness of musical training in children surviving brain tumours

Conditions: Brain Neoplasms; Child

Summary: this study aims to examine the effects of musical training on improving the neurocognitive function and psychological well-being of children surviving brain tumours. half of the participants will receive weekly 45-minute lessons on musical training for one year (52 weeks) while the other half are the placebo controls.

children surviving brain tumours have the highest risk of suffering neurocognitive late effects, such as impairment of intellectual development and deficits in attention and concentration, working memory, processing speed and executive function. such effects severely affect their levels of academic achievement, psychosocial function and quality of life. musical training is considered to have potential for treating neurocognitive impairment,mostly because the extensive brain networks engaged in musical training can induce substantial neuroplasticity changes in cortical and subcortical regions of motor, auditory and speech processing networks. a review of musical training for neuro-rehabilitation revealed that it can enhance motor recovery and neuroplasticity after stroke and improve motor deficits observed in parkinson's disease. a growing body of evidence points to the beneficial effects of musical training on the cognitive development of children. the results of a longitudinal study on the effects of musical training on children's brain and cognitive development demonstrated that such training results in long-term enhancement of visualspatial, verbal and mathematical performance. moreover, engaging in musical practice in childhood predicts academic performance and iq at the university level. thus, there appears to be some support for the effects of music lessons on intellectual development. nevertheless, although musical training is popular and is considered to be a beneficial intervention in the treatment of neurocognitive impairment, longitudinal studies that examine the efficacy of music-making in clinical settings are limited. importantly, there is to date no study that examines the effects of musical training on induction of neuroplasticity in childhood cancer survivors with neurocognitive impairment. there is an imperative need for rigorous empirical scrutiny of the ability of musical training, in particular, to achieve neuroplasticity and thus promote the cognitive function and psychological well-being of children surviving brain tumours.

Eligibility criteria:
inclusion criteria: * surviving germ cell tumours of the brain * be aged from 7 to 19 years * be able to speak cantonese and read chinese * have residual function of the upper extremities (i.e. be able to move the extremities, such as the fingers and arms, without assistance) * have completed treatment for at least two months exclusion criteria: * have undertaken or are undertaking (at the time of the intervention) the study of a musical instrument following their cancer diagnosis * with evidence of cancer recurrence or second malignancy in their medical records
determination of the predictive factors in the reversibility or the aggravation in the disorders of the glucose metabolism in cystic fibrosis patients

Conditions: Diabetes in Cystic Fibrosis Patients

Summary: for some years, the investigators observe an increase of the arisen of diabetes in cystic fibrosis patients however, this diabetes may be reversible. the investigators speak about " cystic fibrosis related diabetes.". the objective of this project, is to know better what facilitates the appearance and the reversibility of the diabetes, such as the genetic mutations, the respiratory state and the lung infections. theses knowledges should allow to adapt the screening of diabetes, and its treatment, for the patients affected by cystic fibrosis.


Eligibility criteria:
inclusion criteria: * cystic fibrosis patients with at least one visit in cystic fibrosis center in rhône-alpes (france) during the second half-year 2008 * patients with disorders or not of the glucose metabolism * patient with pancreatic insufficiency exclusion criteria: * patient with hypoglycemia treatment : insulin or oral antidiabetic * patient with an age \< 10 years * patient with lung transplant

Keywords: cystic fibrosis -diabetes - glucose tolerance - reversibility - oral glucose tolerance test - predictive factors
a trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease

Conditions: Prostate Cancer

Summary: the purpose of this trial is to test if a marketed drug for advanced prostate cancer (firmagon) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (lupron depot) in subjects with prostate cancer and cardiovascular disease.


Eligibility criteria:
inclusion criteria: * advanced prostate cancer * indication to initiate androgen deprivation therapy (adt) * predefined cardiovascular disease exclusion criteria: * previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial) * acute cardiovascular disease in the previous 30 days
pdt vs peels for treatment of actinic keratoses

Conditions: Actinic Keratoses

Summary: the purpose of this study is to to compare photodynamic therapy (pdt) versus the combination of jessner's solution and 35% trichloroacetic acid (tca) chemical peels for the treatment of actinic keratoses on upper extremities. this is a randomized clinical trial. approximately 60 participants with actinic keratoses on both upper arms will be randomized to have one arm receive photodynamic therapy, while the contralateral arm receives jessner's solution followed immediately by 35% tca. aks will be counted before treatment and 2-8 weeks after treatment. this study is a pilot study designed to determine the feasibility of this procedure. subjects currently living in the chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.


Eligibility criteria:
inclusion criteria: 1. \>18 years of age 2. interested in receiving treatment for actinic keratoses on the bilateral upper arms 3. in good general health as assessed by the investigator 4. participants must have the ability to understand and the willingness to sign a written informed consent prior to registration on study exclusion criteria: 1. patient pregnant or nursing 2. patient with extensive concurrent skin conditions (such as eczema, psoriasis, etc) on upper extremities that would interfere with treatment as determined by the treating physician 3. subject unwilling to sign an irb approved consent form 4. participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible
phase ii gallium nitrate in relapsed or refractory non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma; Relapsed Lymphoma; Refractory Lymphoma; Low-Grade Lymphoma; Intermediate-Grade Lymphoma

Summary: eligible patients will have low- or intermediate-grade non-hodgkin's lymphoma (nhl) that has progressed after standard chemotherapy. patients will receive gallium nitrate 300 mg/m2/day by continuous iv infusion for 7 consecutive days using a portable infusion pump. hospitalization is not required. stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.

this study seeks to define the role of gallium nitrate in a specific population of patients who are expected to have received prior therapy. preliminary clinical studies have suggested substantial evidence of antitumor activity in patients with relapsed or refractory non-hodgkin's lymphoma treated with gallium nitrate.

Eligibility criteria:
low- or intermediate-grade nhl using the international working formulation, subtypes iwf a-g: using the updated real/who classification, the following pathologic subtypes are eligible: * small lymphocytic lymphoma * lymphoplasmacytic lymphoma/immunocytoma * follicular lymphoma * diffuse large b-cell lymphoma * peripheral t-cell lymphoma, not otherwise characterized progression of disease following treatment with standard chemotherapy bi-dimensionally measurable disease performance status: ecog \< = 2 patients with mantle cell lymphoma or mycosis fungoides are not eligible patients with known history of cns metastasis are not eligible

Keywords: gallium nitrate ganite nhl relapsed